Literature DB >> 31036456

Development of GEM-PA-nanotrap for purification of foot-and-mouth disease virus.

Haiwei Cheng1, Jin Chen1, Zizheng Cai2, Luping Du1, Jibo Hou1, Xuwen Qiao3, Qisheng Zheng4.   

Abstract

Vaccination is the primary preventative measure against outbreaks of foot-and-mouth disease (FMD). The efficacy of inactivated FMD vaccines is mainly determined by the integrity of foot-and-mouth disease virus (FMDV) particles (referred to as 146S particles), and impurities in the inactivated vaccines could result in side effects. In this study, we developed an effective affinity purification method for the purification of FMDV from cellular lysates, referred to as GEM-PA-nanotrap. To develop the GEM-PA-nanotrap, a nanobody (Nb205) against FMDV vaccine strain O/MYA98/BY/2010 146S particles was selected from a non-immunized library and fused to a peptidoglycan-binding protein anchor (PA). The PA-Nb205 fusion protein was non-covalently coupled to the surface of Gram-positive enhancer matrix (GEM) particles, which were prepared from the non-living, non-genetically modified, Gram-positive, food-grade Lactococcus lactis bacteria. The GEM-PA-nanotrap was used to purify FMDV from cellular lysates through a simple incubation and centrifugation step. The FMDV recovery rate was more than 99%, the efficiency of nonviral protein removal was about 98.3%, and the purification process had almost no effect on the integrity and immunogenicity of 146S particles. Therefore, the GEM-PA-nanotrap has potential as an effective method for the recovery and purification of FMDV during the vaccine manufacturing process.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Affinity purification; FMDV; Gram-positive enhancer matrix particles; Nanobody; Nanotrap

Year:  2019        PMID: 31036456     DOI: 10.1016/j.vaccine.2019.04.078

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Application of Heparin Affinity Chromatography to Produce a Differential Vaccine without Eliciting Antibodies against the Nonstructural Proteins of the Serotype O Foot-and-Mouth Disease Viruses.

Authors:  Sun Young Park; Jung-Min Lee; Ah-Young Kim; Sang Hyun Park; Jae-Seok Kim; Hyejin Kim; Jung-Won Park; Jong-Hyeon Park; Young-Joon Ko; Choi-Kyu Park
Journal:  Viruses       Date:  2020-12-07       Impact factor: 5.048

2.  Bacterium-Like Particles Displaying the Rift Valley Fever Virus Gn Head Protein Induces Efficacious Immune Responses in Immunized Mice.

Authors:  Shengnan Zhang; Feihu Yan; Dongping Liu; Entao Li; Na Feng; Shengnan Xu; Hualei Wang; Yuwei Gao; Songtao Yang; Yongkun Zhao; Xianzhu Xia
Journal:  Front Microbiol       Date:  2022-03-17       Impact factor: 5.640

3.  GEM-PA-Based Subunit Vaccines of Crimean Congo Hemorrhagic Fever Induces Systemic Immune Responses in Mice.

Authors:  Qi Wang; Shen Wang; Zhikang Shi; Zhengrong Li; Yongkun Zhao; Na Feng; Jinhao Bi; Cuicui Jiao; Entao Li; Tiecheng Wang; Jianzhong Wang; Hongli Jin; Pei Huang; Feihu Yan; Songtao Yang; Xianzhu Xia
Journal:  Viruses       Date:  2022-07-28       Impact factor: 5.818

4.  Polymer Particles Bearing Recombinant LEL CD81 as Trapping Systems for Hepatitis C Virus.

Authors:  Dmitry Polyakov; Ekaterina Sinitsyna; Natalia Grudinina; Mariia Antipchik; Rodion Sakhabeev; Viktor Korzhikov-Vlakh; Mikhail Shavlovsky; Evgenia Korzhikova-Vlakh; Tatiana Tennikova
Journal:  Pharmaceutics       Date:  2021-05-07       Impact factor: 6.321

5.  A Novel Bacterium-Like Particle-Based Vaccine Displaying the SUDV Glycoprotein Induces Potent Humoral and Cellular Immune Responses in Mice.

Authors:  Shengnan Xu; Cuicui Jiao; Hongli Jin; Wujian Li; Entao Li; Zengguo Cao; Zhikang Shi; Feihu Yan; Shengnan Zhang; Hongbin He; Hang Chi; Na Feng; Yongkun Zhao; Yuwei Gao; Songtao Yang; Jianzhong Wang; Hualei Wang; Xianzhu Xia
Journal:  Viruses       Date:  2019-12-11       Impact factor: 5.048

Review 6.  Nanotechnology-based antiviral therapeutics.

Authors:  Malobika Chakravarty; Amisha Vora
Journal:  Drug Deliv Transl Res       Date:  2021-06       Impact factor: 4.617

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.